相关实验视频

Updated: May 12, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

结构优化和MD模拟研究西米达衍生物作为强大的突变FLT3激酶抑制剂针对AML

Nada Alaa El-Deen¹, RosaAnna DeFilippis², Amal Kamal Abdel-Aziz^3,4

¹Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.

Archiv der Pharmazie

|May 10, 2025

概括

研究人员开发了一种新化合物,22b,该化合物有效抑制了急性髓性白血病 (AML) 中的FMS类铁酶3 (FLT3) 突变. 这种新型FLT3抑制剂通过选择性向具有减少骨髓抑制潜力的癌细胞,对治疗耐药AML充满希望.

科学领域:

药用化学医学化学
血液学血液学血液学
分子生物学分子生物学

背景情况:

急性髓性白血病 (AML) 是一种具有不良结果的侵袭性癌症,通常是由FMS类型的氨酸激酶3 (FLT3) 突变驱动的.
FLT3突变给现有疗法带来了耐药性,突出显示了对新型治疗策略的需求.
之前的研究发现了一种基于本齐米达的抑制剂,4ACP,对FLT3突变具有活性.

研究的目的:

合成和评估新型西米达衍生物作为FLT3突变的强效抑制剂.
确定一种具有增强活性和选择性的化合物,用于向耐药AML.

主要方法:

通过修改4 - 乙胺基组和N1-/C2替代剂,合成了31种胺醇衍生物.
对FLT3-ITD和FLT3-TKD突变的评估抑制活性,包括D835Y.
评估了对AML细胞系的抗增殖作用,并评估了针对其他激酶 (如KIT) 的选择性.
进行了分子动力学研究,以了解结构-活动关系.

主要成果:

化合物21l显示出FLT3-TKD的强烈抑制 (IC50 = 1.47 nM).
与溶剂可访问组相关的衍生品22b,对FLT3-TKD{D835Y}表现出亚纳米分子活性 (IC50 = 0.48 nM).
化合物22b对FLT3突变的AML细胞系表现出优选的抗增殖活性,对KIT显著的选择性 (80倍).
在低纳米分子度下,22b诱导细胞循环停止和细胞亡,与FLT3信号通路的剂量依赖抑制.

结论:

化合物22b是突变FLT3,特别是FLT3-TKD (D835Y) 的高度强效和选择性抑制剂.
这些发现确立了22b作为对抗耐药AML的进一步开发的有希望的候选者.
选择性概况表明,在减少骨髓抑制的情况下,潜在的安全边际可能是有利的.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.班齐米达的使用情况这是一种激酶抑制剂 (kinase inhibitor).分子动力学分子动力学突变的 FLT3 病毒.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...